Monte Rosa Therapeutics, Inc.
GLUE
$18.15
-$0.53-2.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.21M | 2.78M | 12.77M | 23.19M | 84.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.21M | 2.78M | 12.77M | 23.19M | 84.93M |
| Cost of Revenue | 41.83M | 39.89M | 34.65M | 29.05M | 30.11M |
| Gross Profit | -37.62M | -37.11M | -21.88M | -5.85M | 54.82M |
| SG&A Expenses | 12.42M | 12.60M | 11.09M | 9.70M | 10.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.24M | 52.50M | 45.74M | 38.75M | 40.89M |
| Operating Income | -50.03M | -49.72M | -32.98M | -15.55M | 44.04M |
| Income Before Tax | -44.45M | -46.08M | -30.26M | -11.10M | 47.71M |
| Income Tax Expenses | 52.00K | 59.00K | -3.18M | 1.20M | 822.00K |
| Earnings from Continuing Operations | -44.50M | -46.14M | -27.08M | -12.30M | 46.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.50M | -46.14M | -27.08M | -12.30M | 46.89M |
| EBIT | -50.03M | -49.72M | -32.98M | -15.55M | 44.04M |
| EBITDA | -48.01M | -47.63M | -30.88M | -13.43M | 46.08M |
| EPS Basic | -0.45 | -0.54 | -0.33 | -0.15 | 0.57 |
| Normalized Basic EPS | -0.28 | -0.34 | -0.23 | -0.08 | 0.36 |
| EPS Diluted | -0.45 | -0.54 | -0.33 | -0.15 | 0.57 |
| Normalized Diluted EPS | -0.28 | -0.34 | -0.23 | -0.08 | 0.36 |
| Average Basic Shares Outstanding | 99.88M | 85.55M | 82.40M | 82.19M | 82.15M |
| Average Diluted Shares Outstanding | 99.88M | 85.55M | 82.40M | 82.19M | 82.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |